OBJECTIVES: The endovascular aneurysm repair (EVAR) trials aim to assess the efficacy of EVAR in the treatment of AAA in terms of mortality, quality of life, durability and cost-effectiveness. DESIGN:Male and female patients aged at least 60 years with an AAA diameter measuring at least 5.5 cm on acomputed tomography (CT) scan are assessed for anatomical suitability for EVAR. Suitable patients are offered entry either into EVAR Trial 1 if they are considered fit for conventional open repair or EVAR Trial 2 if they are considered unfit. EVAR 1 randomly allocates patients to EVAR or open repair and EVAR 2 randomly allocates patients to EVAR with best medical treatment or best medical treatment alone. Target recruitment for EVAR Trials 1 and 2 is 900 and 280 patients, respectively. PROGRESS: Recruitment began in September 1999 and there are currently 40 UK centres participating in the trials. Monthly targets are being exceeded in EVAR Trial 1 with 1037 patients randomised by October 2003. EVAR Trial 2 is also meeting monthly targets with a total of 319 patients randomised. When recruitment closes in December 2003 patients will need to be followed for at least 1 year from their operation. Publication of full results for both trials is expected in mid 2005.
RCT Entities:
OBJECTIVES: The endovascular aneurysm repair (EVAR) trials aim to assess the efficacy of EVAR in the treatment of AAA in terms of mortality, quality of life, durability and cost-effectiveness. DESIGN: Male and female patients aged at least 60 years with an AAA diameter measuring at least 5.5 cm on a computed tomography (CT) scan are assessed for anatomical suitability for EVAR. Suitable patients are offered entry either into EVAR Trial 1 if they are considered fit for conventional open repair or EVAR Trial 2 if they are considered unfit. EVAR 1 randomly allocates patients to EVAR or open repair and EVAR 2 randomly allocates patients to EVAR with best medical treatment or best medical treatment alone. Target recruitment for EVAR Trials 1 and 2 is 900 and 280 patients, respectively. PROGRESS: Recruitment began in September 1999 and there are currently 40 UK centres participating in the trials. Monthly targets are being exceeded in EVAR Trial 1 with 1037 patients randomised by October 2003. EVAR Trial 2 is also meeting monthly targets with a total of 319 patients randomised. When recruitment closes in December 2003 patients will need to be followed for at least 1 year from their operation. Publication of full results for both trials is expected in mid 2005.
Authors: Thom W Rooke; Alan T Hirsch; Sanjay Misra; Anton N Sidawy; Joshua A Beckman; Laura K Findeiss; Jafar Golzarian; Heather L Gornik; Jonathan L Halperin; Michael R Jaff; Gregory L Moneta; Jeffrey W Olin; James C Stanley; Christopher J White; John V White; R Eugene Zierler Journal: J Am Coll Cardiol Date: 2011-10-06 Impact factor: 24.094
Authors: Thom W Rooke; Alan T Hirsch; Sanjay Misra; Anton N Sidawy; Joshua A Beckman; Laura K Findeiss; Jafar Golzarian; Heather L Gornik; Jonathan L Halperin; Michael R Jaff; Gregory L Moneta; Jeffrey W Olin; James C Stanley; Christopher J White; John V White; R Eugene Zierler Journal: Catheter Cardiovasc Interv Date: 2011-09-29 Impact factor: 2.692
Authors: David C Brewster; John E Jones; Thomas K Chung; Glenn M Lamuraglia; Christopher J Kwolek; Michael T Watkins; Thomas M Hodgman; Richard P Cambria Journal: Ann Surg Date: 2006-09 Impact factor: 12.969
Authors: Randall R De Martino; Benjamin S Brooke; William Robinson; Andres Schanzer; Jeffrey E Indes; Jessica B Wallaert; Brian W Nolan; Jack L Cronenwett; Philip P Goodney Journal: Circ Cardiovasc Qual Outcomes Date: 2013-09-01